- PuriflOH (PO3) is teaming up with Aspen Medical to supply its air disinfection technology
- Aspen is a global healthcare solutions provider and one of the Australian Government’s COVID-19 response providers
- Under the Heads of Agreement, PuriflOH will provide air conditioner coil disinfection technologies and a whole-of-room air purifier for field pilot sites
- At this point, the arrangement is non-binding but outlines the companies’ intentions to enter an exclusive supply and distribution agreement
- PO3 shares last traded at $1.37 on May 11, 2021
PuriflOH (PO3) is teaming up with global healthcare solutions provider Aspen Medical to supply its air disinfection technology.
Aspen is one of several companies chosen by the Australian Federal Government to assist with the COVID-19 vaccine rollout by providing extra immunisation workforce. Aspen has also been engaged to roll out COVID-19 vaccines in the U.S. and the UAE.
Under the Heads of Agreement, PuriflOH will provide air conditioner coil disinfection technologies and a whole-of-room air purifier for field pilot sites.
“We are very pleased to be partnering with PuriflOH. The FRG technology is a powerful addition to our general infection control regimes for high-traffic enclosed spaces,” said Aspen Executive Chairman and Founder Glenn Keys AO.
“Our technology delivers the assurance of superior air disinfection, not simply purification alone. The powerful free radicals are short-lived, rapidly decomposing into water and oxygen after the disinfection,” said PuriflOH Technical Director Dr Alex Sava.
Third-party testing of the technology has previously validated it to be 99.99 per cent effective against airborne biological and chemical contaminants.
At this point, the arrangement is non-binding but outlines the companies’ intention to enter an exclusive supply and distribution agreement.
PO3 shares last traded at $1.37 on May 11, 2021.